Novel perspectives of sodium handling in type 2 diabetes mellitus

References

• Patel S, Rauf A, Khan H, et al. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317–325.
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides. 2019;111:18–25.
   PubMed Web of Science ®Google Scholar
• Manning RD Jr., Guyton AC. Dynamics of fluid distribution between the blood and interstitium during overhydration. Am J Physiol. 1980;238(5):H645–51.
   PubMedGoogle Scholar
• Bentley B. A review of methods to measure dietary sodium intake. J Cardiovasc Nurs. 2006;21(1):63–67.
   PubMedGoogle Scholar
• McLean RM, Farmer VL, Nettleton A, et al. Assessment of dietary sodium intake using a food frequency questionnaire and 24-hour urinary sodium excretion: a systematic literature review. J Clin Hypertens (Greenwich). 2017;19(12):1214–1230.
   PubMed Web of Science ®Google Scholar
• Ji C, Sykes L, Paul C, et al. Systematic review of studies comparing 24-hour and spot urine collections for estimating population salt intake. Rev Panam Salud Publica. 2012;32(4):307–315.
   PubMedGoogle Scholar
• Birukov A, Rakova N, Lerchl K, et al. Ultra-long-term human salt balance studies reveal interrelations between sodium, potassium, and chloride intake and excretion. Am J Clin Nutr. 2016;104(1):49–57.
   PubMedGoogle Scholar
• Jantsch J, Schatz V, Friedrich D, et al. Cutaneous Na+ storage strengthens the antimicrobial barrier function of the skin and boosts macrophage-driven host defense. Cell Metab. 2015;21(3):493–501.
   PubMed Web of Science ®Google Scholar
• Hanson P, Philp CJ, Randeva HS, et al. Sodium in the dermis colocates to glycosaminoglycan scaffold, with diminishment in type 2 diabetes mellitus. JCI Insight. 2021; 6(12). DOI: https://doi.org/10.1172/jci.insight.145470
   Google Scholar
• Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018;17(1):5.
   PubMedGoogle Scholar
• Wiig H, Luft FC, Titze JM. The interstitium conducts extrarenal storage of sodium and represents a third compartment essential for extracellular volume and blood pressure homeostasis. Acta Physiol. 2018;222(3):e13006.
   Google Scholar
• Kopp C, Linz P, Maier C, et al. Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by (23)Na magnetic resonance imaging. Kidney Int. 2018;93(5):1191–1197.
   PubMedGoogle Scholar
• Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520–526.
   PubMed Web of Science ®Google Scholar
• Kannenkeril D, Jung S, Harazny J, et al. Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021;35(12):108055.
   PubMedGoogle Scholar
• Schepkin VD, Neubauer A, Nagel AM, et al. Comparison of potassium and sodium binding in vivo and in agarose samples using TQTPPI pulse sequence. J Magn Reson. 2017;277:162–168.
   PubMedGoogle Scholar
• Maroudas A, Bannon C, Silberberg A. Measurement of swelling pressure in cartilage and comparison with the osmotic pressure of constituent proteoglycans. Biorheology. 1981;18(3–6):619–632.
   PubMedGoogle Scholar
• Bathe M, Rutledge GC, Grodzinsky AJ, et al. A coarse-grained molecular model for glycosaminoglycans: application to chondroitin, chondroitin sulfate, and hyaluronic acid. Biophys J. 2005;88(6):3870–3887.
   PubMedGoogle Scholar
• Chahine NO, Chen FH, Hung CT, et al. Direct measurement of osmotic pressure of glycosaminoglycan solutions by membrane osmometry at room temperature. Biophys J. 2005;89(3):1191–1197.
   Google Scholar
• O’Hare JP, Corrall RJ. De natrio diabeticorum. increased exchangeable sodium in diabetes. Diabet Med. 1988;5(1):22–26.
   PubMedGoogle Scholar
• Ellison DH, Welling P, Ingelfinger JR. Insights into salt handling and blood pressure. N Engl J Med. 2021;385(21):1981–1993.
   PubMedGoogle Scholar
• Piccirillo G, Feuerer N, Carvajal Berrio DA, et al. Hyaluronic acid-functionalized hybrid gelatin-Poly-L-Lactide scaffolds with tunable hydrophilicity. Tissue Eng Part C Methods. 2021;27(11):589–604.
   PubMedGoogle Scholar
• Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 2010;339(1):237–246.
   PubMed Web of Science ®Google Scholar
• Merry CLR, Lindahl U, Couchman J, et al. Proteoglycans and sulfated glycosaminoglycans. In: th VA, Cummings RD, Esko JD, et al., editors. Essentials of glycobiology. Long Island, New York: Cold Spring Harbor Laboratory Press; 2022. p. 217–232.
   Google Scholar
• Zhang L. Glycosaminoglycans in development, health and disease. Preface Prog Mol Biol Transl Sci. 2010;93:xvii–xviii.
   PubMedGoogle Scholar
• Oien AH, Wiig H. Electrostatic, elastic and hydration-dependent interactions in dermis influencing volume exclusion and macromolecular transport. J Theor Biol. 2016;400:80–91.
   PubMedGoogle Scholar
• O’Hare JA, Ferriss JB, Brady D, et al. Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension. 1985;7(6 Pt 2):II43–8.
   PubMedGoogle Scholar
• de Chatel R, Weidmann P, Flammer J, et al. Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. Kidney Int. 1977;12(6):412–421.
   PubMedGoogle Scholar
• De Chatel R, Toth M, Barna I, et al. Body sodium, atrial natriuretic peptide and blood pressure in diabetes mellitus. Acta Biomed Ateneo Parmense. 1992;63(1–2):153–161.
   PubMedGoogle Scholar
• Pavlou DI, Paschou SA, Anagnostis P, et al. Hypertension in patients with type 2 diabetes mellitus: targets and management. Maturitas. 2018;112:71–77.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–610.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83.
   PubMed Web of Science ®Google Scholar
• Brands MW, Manhiani MM. Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul Integr Comp Physiol. 2012;303(11):R1101–9.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia. 1981;21(3):165–171.
   PubMed Web of Science ®Google Scholar
• Brimble A, Corrall R, Mattocks J, et al. Insulin and the renal response to volume expansion in man (A). J Physiol (London) 1985; 66
   Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Dekkers CCJ, Gansevoort RT, Heerspink HJL. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diab Rep. 2018;18(5):27.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643–1658.
   PubMed Web of Science ®Google Scholar
• Salvatore T, Caturano A, Galiero R, et al. Cardiovascular benefits from gliflozins: effects on endothelial function. Biomedicines. 2021;9(10):1356.
   PubMed Web of Science ®Google Scholar
• Palmiero G, Cesaro A, Vetrano E, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22(11):5863.
   PubMed Web of Science ®Google Scholar
• Abdulrahman N, Ibrahim M, Joseph JM, et al. Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression. Mol Cell Biochem. 2022;477(6):1865–1872.
   PubMedGoogle Scholar
• Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–573.
   PubMed Web of Science ®Google Scholar
• Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722–726.
   PubMed Web of Science ®Google Scholar
• Packer M. Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors. Circ Heart Fail. 2020;13(9):e007197.
   PubMed Web of Science ®Google Scholar
• Karmazyn M. NHE-1: still a viable therapeutic target. J Mol Cell Cardiol. 2013;61:77–82.
   PubMed Web of Science ®Google Scholar
• Cechowska-Pasko M, Palka J, Bankowski E. Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity. Mol Cell Biochem. 1996;154(1):1–8.
   PubMedGoogle Scholar